Niagen Bioscience (NAGE) Current Deferred Revenue (2011 - 2026)
Niagen Bioscience (NAGE) reported Current Deferred Revenue of $380000.0 for Q1 2026, up 83.57% year-over-year from $207000.0 in Q1 2025, and down 4.76% quarter-over-quarter from $399000.0 in Q4 2025.
Niagen Bioscience (NAGE) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 13 years of Current Deferred Revenue data on file, last reported at $380000.0 in Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $380000.0, up 83.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $380000.0 (up 83.57% YoY), and the FY2025 annual result was $399000.0, down 34.7% from the prior year.
- Current Deferred Revenue eased to $380000.0 in Q1 2026 per NAGE's latest filing, from $399000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $611000.0 in Q4 2024 and troughed at $141000.0 in Q1 2022.
- A 5-year average of $240352.9 and a median of $189000.0 in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue soared 213.33% in 2024, then slumped 34.7% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $157000.0 in 2022, then increased by 24.2% to $195000.0 in 2023, then soared by 213.33% to $611000.0 in 2024, then plunged by 34.7% to $399000.0 in 2025, then decreased by 4.76% to $380000.0 in 2026.
- Business Quant data shows NAGE's Current Deferred Revenue at $380000.0 in Q1 2026, $399000.0 in Q4 2025, and $292000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Niagen Bioscience | 269.32 Mn | 202.77 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 380,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Dec 31, 2024 | 611,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 227,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 189,000.00 |
| Jun 30, 2023 | 166,000.00 |
| Mar 31, 2023 | 148,000.00 |
| Dec 31, 2022 | 157,000.00 |
| Sep 30, 2022 | 158,000.00 |
| Jun 30, 2022 | 173,000.00 |
| Mar 31, 2022 | 141,000.00 |
| Dec 31, 2021 | 161,000.00 |
| Sep 30, 2021 | 175,000.00 |
| Jun 30, 2021 | 210,000.00 |